01:44 , Aug 16, 2019 |  BC Innovations  |  Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

As the NLRP3 field gains momentum, drawing VC and pharma interest for the role the target plays in diseases ranging from NASH to neurodegeneration, biotechs are beginning to eye the next crop of inflammasome targets....
00:24 , Apr 12, 2019 |  BC Innovations  |  Product Development

NLRP3 early and often

Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target -- NLRP3 -- is gaining momentum, but...
23:23 , Mar 27, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Multiple myeloma (MM) Patient sample and mouse studies suggest inhibiting IL-18 or NLRP1 could help treat MM. In patient samples, high bone marrow plasma levels of IL-18 correlated with poor overall survival. In two...
01:10 , Aug 11, 2017 |  BC Innovations  |  Strategy

The flip-side of immunotherapy

In the smaller print of last week’s deal between IFM Therapeutics Inc. and Bristol-Myers Squibb Co. was the latest example of a growing trend of companies aiming to draw extra value out of a cancer...
07:00 , Jun 11, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Inflammation

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation NLR family pyrin domain containing 1 (NLRP1; NALP1); NLRP3 (NALP3) In vitro and mouse studies suggest that inhibiting NLRP1 and...